In the latest development, NurExone has developed two selective small inhibiting RNA sequences (siRNA) that target and inhibit proteins within the Peri-Neural Network (PNN) complex (Fig. 1A). The breakthrough sequences, detailed in a patent application held by the Company, are built upon a scientifically validated strategy for enhanced neuronal regeneration via inhibition of the PNN complex. The Company believes that its innovative approach, using the Company’s ExoTherapy platform to deliver these RNA sequences, will overcome limitations of previous methods. This marks a potential for two new products in the Company’s portfolio. The promise of the Company’s new sequences is evident in Figures 1B-1C, where PNN is notably reduced post-treatment.
ExoPTEN, the Company’s first product under development, employs a distinct mechanism of action while sharing the same exosome-based drug delivery system. ExoPTEN has progressed to rat models, displaying regenerative properties and restoration of motor function, with human trials anticipated in the foreseeable future.
Dr.
Dr.
Figure 1:
(A) Illustration of the extracellular Perineural network (PNN), highlighted in green.
(B) Immunohistology of one protein in the PNN in differentiated neuronal culture demonstrate that the new treatment on human neuronal culture successfully degraded the PNN.
(C) Quantification of one PNN building block protein that was successfully inhibited by the new treatment.
About
For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.
For more information, please contact:
Dr.
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com
Investment Relation -
Phone: +1 905-347-5569
Email: IR@nurexone.com
Dr.
Investment Relation -
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu
FORWARD-LOOKING STATEMENTS
This press release contains certain “forward-looking statements”, that reflect the Company’s current expectations and projections about its future results. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to the Company’s ExoTherapy drug, ExoPTEN. These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof.
In developing the forward-looking statements in this press release, we have applied several material assumptions, including our ability to retain key personnel, our ability to continue investing in research and development, our ability to secure available funding and to continue as a going concern, the general business and economic conditions of the industries and countries in which we operate, our ability to execute on our business strategy, that there will be certain amount of demand for the Company’s potential product, inflation will remain stable, and that the results of our studies reflect results that can be extrapolated.
Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the Company’s early stage of development, lack of revenues to date, government regulation, market acceptance for its products, rapid technological change, dependence on key personnel, protection of the Company’s intellectual property, dependence on the Company’s strategic partners and the risks discussed under the heading “Risk Factors” on pages 29 to 36 of the Company’s Annual Information Form dated
Neither
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d1febbe6-921b-431a-b844-a814be12e06b
The PNN as new target for NurExone’s ExoTherapy platform.
(A) Illustration of the extracellular Perineural network (PNN), highlighted in green. (B) Immunohistology of one protein in the PNN in differentiated neuronal culture demonstrate that the new treatment on human neuronal culture successfully degraded the PNN. (C) Quantification of one PNN building block protein that was successfully inhibited by the new treatment.
2023 GlobeNewswire, Inc., source